Member Info for Aldebaran

Nsider shorting but not decided either way yet

Definitely see single digit share price in near term.

What's going on with this company hydrogen meant to be the future. Is it to far into the future though is that the problem

Actually looks like the raise was forward sold anyhow. Chart came up on my alerts to co

Am I reading the interim right?

Afc energy made 400k in sales

Yet has a market cap at over 100 million great British pounds

How much growth yall expecting here exactly as the revenues need to massively MASSIVELY ramp up. Exponentially even, just to justify the current valuation.

I'm surprised they got a raise away at 15p. Maybe I'm missing something lol

I think the valuation of AFC energy needs to come down somewhere closer to 50m mark to make it worth the risk or sales need to ramp up exponentially

I ask again, what are peoples thoughts on the price action here. There are always insider leaks so in run up to financial release I'd expect to see strong uptrend whereas we're seeing exact opposite here. I think BOOM is heading for an mighty drop. If people want to put an alternative view I'm all ears but let's stick to the point and not start with the insults of the person ect

Is this price action bullish yes or no and why

Does anybody want to talk about the price action then? Or just try to play the man instead of the ball?

If those buys and sells are right. Why is boom down AGAIN.

Why does the chart look like a bag of .... ?

Why are director buys and great accounts due not creating any positivity and positive share price action? I guess the market has it wrong does it guys lol

Would you guys say price action is bullish or bearish?

Leading upto a financial update the price action concerns me personally. The share price isn't e enough supported by directors buying.

Close above 200dma today

Holiday season allbutover

News flow inbound

Going to be a GLORIOUS period for anyone holding these shares

Ava3996 has gone and the real question is WHY ?

What exactly have they seen in pre clinical pipeline drugs. Cytotoxics so powerful they were set aside but now perhaps modified with precision they are showing efficacy far beyond what 3996 ever was?

3996 has been dropped for a reason is what I'm saying

Y'all spend to much time talking about each other than you do avacta it's a bit weird an I ain't interested. I skim the BB purely for avacta info and ignore 90% of what is posted. I post stuff that might be relevant and sometimes share twitter posts as I know many don't have twitter or are in the naughty block list of the boiler room rah and Co. It's to help other investors only. I ain't interested in any name calling or people real identification or none of that stuff. If yall wanna waste your time with it fine. Own decision. My first and last post on this nonsense

News starting to get out now.

I think it'd help if we all tagged any Scientific and medical journals plus news outlets into are tweets and even emailed some of them with key information. I have started doing this already

Touk was only asking what impact CC has had on the business during her short tenure yesterday as he couldn't think of anything. A list of the thing she's done was then provided and touk.... well we didn't hear from him again about that topic.

Reading those transcripts 1 thing that people are confused about is the for sale sign. This absolutely does not apply to selling off diagnostics lol

They are talking about a business that is up for sale and Christina made it clear during the Q&A of the AGM that any sale takes care of itself, her and the team are pressing ahead on the basis they'll be independent (knowing they'll be taken over of course but planning for the future as if they won't).

Also yes BP want certainty and short time to big revenues well av6k starting to replace dox by 2026 is pretty much nailed on aa certain as you can get. Annual sales are what, 1bn+ & av6k can expand that market plus there is off-label use etc... so by 2030 is it unrealistic to think any acquiring company could be selling 1.5bn pa of av6k? Put that on a 5x multiplier and you've got 7.5bn valuation for avacta right there. Or a 25-bagger from this level.

That's without factoring in the pipeline.

And remember this important point. It is a delivery platform avacta are selling. Vastly different to anything else.

Also remember the patent cliffs these guys are all facing and just how much money they have built up and you can easily get a valuation of xxbn

If there is a bidding war then especially the valuation will take care of itself.

She doesn't have to be in office for Avacta to release an RNS. It comes when it comes the company can't sit o material nwws

Pivot to peptide drug conjugate and has paid HCI loan payment in cash as well. Plus 3996 has been dropped.

Touk you are not invested here it is so obvious haha

Nothing you trolls say will make any difference. Avactas precision is putting therapeutic levels of dox into the tumour. They are dosing patients with 3.5x normal level of straight dox. A number of terminals patients are seeing stable disease and progression free survival with none of the nasty side effects. Avacta are now dosing patients every 2 weeks such is the improved safety profile in what can only be described as a mini efficacy study. The company valuation remains at a fraction of what ava6k sales will be. Investors here see through you. Avacta is a winning stock from this level you can't go wrong

Pivot to peptide drug conjugate and has paid HCI loan payment in cash as well.

Touk you are not invested here it is so obvious haha

Nothing you trolls say will make any difference. Avactas precision is putting therapeutic levels of dox into the tumour. They are dosing patients with 3.5x normal level of straight dox. A number of terminals patients are seeing stable disease and p

Yerrr, this bulletin board isn't just yours though is it mate. You know where the filter button is.

C1, Q2W (160/108mg)

Days to complete: 64

Cumulative dose: 1,760/1,188mg

Scans: 2

C2, Q2W (200/135mg)

Days to complete: 35

Cumulative dose: 1,200/810mg

Scans: 2

C3, Q2W (250/169mg)

Days to complete: 59 (ongoing)

Cumulative dose: 1,000/676mg

Scans: 1

What about beyond just cancer treatment? A partnership with Daewoong Pharmaceuticals to form Affyxell is looking into having mesenchymal cells either express or secrete proprietary Affirmers to target conditions like MS, type 1 diabetes, graft versus host disease (GvHD) and solid organ transplant rejection.

The possibilities to come from a platform which is already proven to be safe and effective are truly mind blowing.

It is absolutely baffling to me that others cannot understand the immense value and opportunities Avacta offer, and try to smear a team of world leading scientists tackling oncology’s most difficult problem. Clinicians and big pharma definitely won’t miss this though, and in the end that’s what’s going to matter.

Ask yourself this: if you or a loved one was diagnosed with a soft tissue cancer, would you want the naked drug with a track record of life-ruining (and potentially life ending) side effects, or AVA6000, which can be given at a higher dose, more frequently and for longer, with vastly reduced side effects. I know what I’d be asking for - and that’s before we have data from the official efficacy studies, which I’m certain will show hugely favourable outcomes.

This company will genuinely change oncology forever, and improve both the treatment outcomes and quality of life for patients going forwards.

I think I speak for all clinicians, patients and shareholders when I say that we are all behind the entire team - from CEO to lab technicians - and cannot wait for their continued successes to be published.

What a few months and years we have coming up!

And that’s just the start. The pathfinder. The platform prover. Any pharma analyst will tell you their industry depends on pipelines - no pipeline, no party. Just as well Avacta have already hinted at what’s to come, and plan to release full details and timescales of their pipeline by the end of the year.

More precision protected cytotoxic cancer killing drugs, which can lean on decades worth of clinical data for safety profiling and efficacy - as the beauty here is these would not be classified as new drugs and instead modified drugs - negating the need to go through lengthy expensive trials.

The Affirmer platform - 10 times smaller than an antibody with 10,000,000,000 different phage combinations to make small, cheap highly flexible solutions for previously difficult to drug targets such as G-protein coupled receptors. Do you want one specific target, or multiple targets in one molecule? This can do whatever you want. How about if you wanted to link an affirmer to precision, giving first in class therapeutic possibilities.

Clear proof of concept shown by the 2 log difference between blood concentration and tumour concentration of drug when measured.

Clear efficacy shown in end of life patients who had already been heavily pretreated to no avail. This has been shown in the phase 1a dose escalation study which is designed purely to look at safety and tolerability - not efficacy. This is shown in a mix of patients, some of whom have cancers not usually treated by anthracyclines.

Think what the efficacy data will be once we move into the phase 1b expansion cohorts then into phase 2 efficacy studies where patients with cancers typically treated by anthracyclines are selected.

After re-reading and rewatching all content on #AVCT website, it really is hard to downplay the vast potential this platform has.

A wrapper for toxic drugs enabling higher doses to be given more frequently and for longer.

What pharma company wouldn’t want to be able to sell more drug for a longer period of time.

What patient wouldn’t want fewer life threatening, misery inducing side effects during their cancer treatments.

What treating clinician wouldn’t want to give a safer more pleasant drug to their patients with higher specificity and efficacy.